Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's largest healthcare company, with a market cap that topped $860 billion at one point.However, note the caveats used to describe Lilly's big run: "almost" and "at one point." Over the last eight weeks, the big pharma stock has pulled back significantly. This decline includes a sell-off earlier this week after Lilly cut its 2024 revenue guidance due to lower-than-expected demand for its obesity and diabetes drugs. The drugmaker might soon get some help, though, from a perhaps surprising source. Could Donald Trump make Eli Lilly stock a no-brainer buy in 2025?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool